-
1 Comment
Veracyte, Inc is currently in a long term downtrend where the price is trading 61.6% below its 200 day moving average.
From a valuation standpoint, the stock is 98.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 24.3.
Veracyte, Inc's total revenue rose by 16.2% to $35M since the same quarter in the previous year.
Its net income has dropped by 7.9% to $-8M since the same quarter in the previous year.
Finally, its free cash flow grew by 99.0% to $1M since the same quarter in the previous year.
Based on the above factors, Veracyte, Inc gets an overall score of 3/5.
CurrencyCode | EUR |
---|---|
ISIN | US92337F1075 |
Sector | Healthcare |
Industry | Diagnostics & Research |
Exchange | F |
Market Cap | 2B |
---|---|
PE Ratio | 100.74 |
Target Price | 63.17 |
Beta | 2.04 |
Dividend Yield | None |
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 12V.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025